New vaccine labs to test 60 batches per month

July 06, 2021 06:40 pm | Updated July 07, 2021 12:11 am IST - HYDERABAD

Scientists at work at the National Institute of Animal Biotechnology in Miyapur, Hyderabad.

Scientists at work at the National Institute of Animal Biotechnology in Miyapur, Hyderabad.

The two new upcoming vaccine testing facilities at National Institute of Animal Biotechnology,(NIAB) here and the National Centre for Cell Science (NCCS) at Pune, as the Central Drug Laboratory (CDL), for batch testing and quality control of vaccines are expected to test approximately 60 batches of vaccines per month.

Both labs with state-of-the-art lab facilities funded under PM-CARES are geared up to test existing COVID-19 vaccines and other newer ones. This will not only expedite the vaccine manufacture and supply but also be logistically convenient considering that both Pune and Hyderabad are the two vaccine manufacturing hubs, said an official press release.

While the facility at NCCS, Pune, has been notified as Central Drugs Laboratory for testing and lot release of COVID vaccines has been made as per the gazette notification issued by Union Ministry of Health & Family Welfare on June 28, the facility at NIAB here is likely to receive necessary notification shortly.

The Centre had decided to set up these two additional laboratories to facilitate expedited testing and pre-release certification of the vaccines in the wake of the COVID-19 pandemic, and considering the enhanced production of vaccines. Currently, the country has a Central Drugs Laboratory (CDL) at Kasauli, which is the National Control Laboratory for testing and pre-release certification of Immunobiologicals (vaccines and antisera) meant for human use.

The new labs will also be under the department of biotechnology, Union Ministry of Science & Technology, which has been at the forefront contributing to various COVID-related activities like vaccine development, diagnostics and testing, bio-banking and genomic surveillance, in addition to fundamental research and also building a strong ecosystem for translational research.

Both DBT-NCCS and DBT-NIAB have been involved in many aspects of infectious disease related work and have contributed to advancement of cutting-edge research output in frontier areas of biotechnology relevant to human health and disease, the release added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.